ASCO Statement Seeks to Balance Prescription Opioids for Patients With Cancer and Misuse and Abuse PreventionMay 31, 2016
ASCO addresses the complex issues surrounding prescription opioids in a new policy statement. ASCO supports the efforts of multiple federal offices and agencies to prevent and respond to prescription drug abuse, and is also working to protect access to appropriate medical opioid therapy for patients with cancer.
A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.
A blood-based test pinpoints which patients with metastatic colorectal cancer will benefit from treatment with cetuximab.
Researchers have pinpointed the evolutionary process cancer cells use to resist the drug LOXO-101.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
The effectiveness of chemotherapy was enhanced by targeting survivin, a protein that inhibits apoptosis or cell death, according to preclinical research in cells and mouse models of retinoblastoma.
A small, phase I clinical trial indicates the experimental drug guadecitabine is safe in combination with the chemotherapy drug irinotecan, and it may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
Continuation of ceritinib therapy beyond disease progression was associated with prolonged survival, according to results from a retrospective study of the use of ceritinib to treat advanced ALK-positive NSCLC.
Some of our patients receive olanzapine (Zyprexa) as an antiemetic. Is this a typical use of this drug?
Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
The growth of medulloblastoma was inhibited by a new drug in research conducted in cell cultures and mice. This study targeted a particularly aggressive form of the disease driven by the oncogene MYC.
Sulforaphane, found in broccoli and other cruciferous vegetables such as cauliflower and kale, may increase the susceptibility of a subset of cancer to prodrug treatments while avoiding harm to normal tissues.
New research has shed light on how some tumors continue their growth despite treatment with kinase inhibitors, and on how a combination of drugs can yield much better results.
A new drug might help successfully treat mesothelioma, one of the deadliest cancers, according to results from cell culture and mouse xenograft models of the disease.
A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Adding Palbociclib to Fulvestrant Improves Progression-free Survival in Select Women With Metastatic Breast CancerMarch 22, 2016
Progression-free survival was significantly and consistently improved when palbociclib was added to fulvestrant, compared with placebo and fulvestrant, for women with stage IV breast cancer that is hormone-receptor-positive and HER2-negative.
Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).
An implantable device allows large doses of highly toxic drugs to be delivered directly to pancreatic tumors while reducing exposure to the toxic side effects in the rest of the body.
How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?
Medications normally used to treat infections and heart conditions are promising cancer treatments. These drugs were previously not known to have roles in modifying cellular epigenetics.
An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.
The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.
Combining a drug indicated for melanoma with a common cholesterol-lowering drug may control the growth of NSCLC, according to research in fruit flies and human lung cancer cell lines.
Nanoparticles that release a drug only when exposed to near-infrared (NIR) light are a promising drug-delivery agent developed by Canadian researchers.
Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
Exosome serves as a natural nanoparticle delivery system and achieves the same cancer-killing effect on drug-resistant lung cancer as current formulations of drug therapy with 50x less drug.
A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.
A drug currently approved for GI conditions may prevent the development of colorectal cancer, according to researchers who revealed a biological connection between obesity and increased risk for colorectal cancer.
Patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not have prescription drug coverage.
- Specific Lifestyle Factors Can Significantly Affect Cancer Mortality
- New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening
- Vitamin D and Androgen Receptor-Targeted Therapy Are Effective in Triple-Negative Breast Cancer
- Adhering to Patient Preferences Improves Patient Comfort During Skin Cancer Screening
- Vessel-Sparing Radiation Successfully Treats Prostate Cancer, Maintains Quality of Life
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Cancer-related Neuropathy May Respond to Gene Therapy
- Socioeconomic Benefits of Marriage Improve Survival Among Married Patients
- Patient Illness Understanding Is Influenced by Recent Prognosis and Life Expectancy Discussions With Oncology Clinicians
- SRC Kinase Inhibitor Could Be a New Treatment for Breast Cancer
- Drug-Resistant Cancer May Be Combatted With New Generation mTOR Inhibitors
- ASCO Statement Seeks to Balance Prescription Opioids for Patients With Cancer and Misuse and Abuse Prevention
- FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|